Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia

被引:85
作者
Davidson, MH [1 ]
机构
[1] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
关键词
cardiovascular disease; dyslipidaemia; statins;
D O I
10.1517/13543784.11.1.125
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Rosuvastatin is a synthetic enantiomer that is hepatoselective, relatively hydrophilic and has minimal metabolism via the cytochrome P450 3A4 system (similar to pravastatin). Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. The majority of HMG-CoA reductase inhibitory activity in plasma is associated with the parent rosuvastatin compound. In a Phase 11 study, rosuvastatin across a dose range of 1 - 80 mg lowered low-density lipoprotein cholesterol (LDL-C) by 34 - 65%. Phase III trials have demonstrated greater reductions in LDL-C for rosuvastatin compared to atorvastatin as well as greater increases in high-density lipoprotein cholesterol (HDL-C). The drug appears to be well tolerated at all doses up to 80 mg/day. A starting dose of 10 mg will reduce LDL-C by approximately 50%, which should adequately treat most patients to within the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) goals.
引用
收藏
页码:125 / 141
页数:17
相关论文
共 26 条
[1]  
Ballantyne C., 2001, INT S DRUGS AFF LIP
[2]  
BROWN CDA, 2001, ATHEROSCLEROSIS, V2, P90
[3]  
Brown WV, 2001, EUR HEART J, V22, P270
[4]  
Buckett L., 2000, ATHEROSCLEROSIS, V151, P41, DOI 10.1016/S0021-9150(00)80185-9
[5]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[6]  
COOPER KJ, 2001, EUR ASS CLIN PHARM T
[7]   Does differing metabolism by cytochrome p450 have clinical importance? [J].
Davidson M.H. .
Current Atherosclerosis Reports, 2000, 2 (1) :14-19
[8]  
Davidson MH, 2001, J AM COLL CARDIOL, V37, p292A
[9]  
Durrington P, 2001, DIABETOLOGIA, V44, pA165
[10]  
GOTTO A, 2001, INT S DRUGS AFF LIP